MARS 2 trial: the future of pleurectomy decortication in pleural mesothelioma.

Competing Interests: FG reports consulting fees and support for attending meetings or travel from MSD, Novocure, Bristol Myers Squibb, Boehringer Ingelheim, PharmaMar, Novartis, and Pierre Fabre; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Novocure; and participation on a data safety monitoring board or advisory board for MSD, Novocure, Bristol Myers Squibb, PharmaMar, Novartis, and Pierre Fabre. LC reports support for attending meetings or travel from Pierre Fabre. AC-F reports payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daichii Sankyo, Foundation Medicine, Janssen, Medscape, MSD, Roche/Genentech, and Takeda; support for attending meetings or travel from Amgen; being President of the Lung Working Group for the Swiss Society for Clinical Cancer Research; and receipt of institutional grants and research support from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, MSD, and Roche/Genentech.